Answers are grounded in this paper and cite their sources.
Background: Diabetic nephropathy (DN), a leading cause of end-stage renal disease, demands novel therapeutic strategies. This study investigated the ability of Tangshen formula (TSF) to modulate DN via a renoprotective mechanism involving soluble epoxide hydrolase (sEH) - and insulin receptor substrate 2 (IRS2) - dependent phosphatidylinositol-3 kinase (PI3K)/AKT (protein kinase B) - eNOS (endothelial nitric oxide synthase) signaling. Methods: A diabetic rat model with hypermethioninemia was established by administering two intraperitoneal injections of streptozotocin (STZ; 30 mg/kg) and feeding a 2% hypermethioninemia (HM) diet. Rats were divided into normal, STZ, HM+STZ, and TSF (3.6 g/kg/day) groups ( n = 8 each) and treated for 12 weeks. Renal expression of sEH, IRS2, PI3K, AKT, and eNOS was evaluated using quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR), western blot, and immunohistochemistry. Results: Diabetic rats showed a 1.4-2.0-fold increase in sEH mRNA and an 11.3-19.6-fold rise in sEH protein levels, accompanied by an 82%-83% reduction in IRS2 mRNA, a marked decrease in IRS2 phosphorylation (15%-16% of normal), and significant impairment of PI3K/AKT-eNOS signaling. TSF treatment reduced sEH mRNA expression by 30% and protein levels normalized, restored IRS2 expression to 61% of the control value, and improved phosphorylation of PI3K, AKT, and eNOS. Conclusion: TSF confers renoprotection in DN by suppressing sEH overexpression and by reactivating the IRS2-mediated PI3K/AKT-eNOS pathway. TSF has potential as a multi-target therapeutic agent for diabetic microvascular complications.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: